Last updated 2026-07-20
- Raised $6.7M Series A led by Rhodium, Mar 2022
- Raised $1M grant led by BIRD Foundation, May 2026
- Raised grant led by National Multiple Sclerosis Society, May 2025
Total raised
$7.7M
Last: Undisclosed Round 2026-05
Stage
Series A
Founded
2005
Headcount
5
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
NeuroGenesis is a clinical-stage cellular therapy company focused on developing novel and effective treatments for neurodegenerative diseases. The company's proprietary NG CELL™ platform utilizes a unique subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating and regenerative biofactory cells. This technology aims to slow and halt neurodegeneration in patients with debilitating neurological diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
Funding history · 3 rounds · $7.7M total
2026-05
Grant
$1.0M
★ BIRD Foundation
2025-05
Grant
Undisclosed
★ National Multiple Sclerosis Society★ National Multiple Sclerosis Society's Fast Forward Program★ National MS Society's Fast Forward programNational MS Society's Fast Forward Program
2022-03
A Round
$6.7M
★ Hadasit★ Rhodium★ Morgan Stanley★ Excell Partners★ Daniel Recanati★ New York Ventures★ one undisclosed investor★ New York State Office of Community Renewal
Headcount over time
From 33 (2023-06) to 29 (2023-12) · -4 (-12%) · 5 points · source: Finder history + radar grounding
Q&A
- What is Neurogenesis's primary focus?
- Neurogenesis is a clinical-stage cellular therapy company focused on utilizing a proprietary subpopulation of bone marrow stem cells to treat central nervous system diseases like progressive multiple sclerosis and amyotrophic lateral sclerosis.
- When was Neurogenesis founded?
- Neurogenesis was founded in September 2018.
- How many employees does Neurogenesis have?
- Neurogenesis has 1-10 employees.
- What is Neurogenesis's total funding to date?
- Neurogenesis has raised a total of $7,660,000.
- When was Neurogenesis's most recent funding round and who participated?
- In May 2026, Neurogenesis received a grant of $1,000,000 from BIRD Foundation.
- Which investors participated in Neurogenesis's March 2022 funding round?
- In March 2022, Rhodium and Excell Partners participated in a private funding round for Neurogenesis.
- Who are the co-founders of Neurogenesis?
- The co-founders of Neurogenesis are Tal Gilat (CEO), Ibrahim Kassis (CTO), and Dimitrios Karussis (CSO).
- Where is Neurogenesis headquartered?
- Neurogenesis is headquartered in Ramat Gan, Israel.
Team · 4
Dimitrios Karussis
Founder · Founder
Tal Gilat
Founder · Founder & CEO
Ibrahim Kassis
Founder · Co-Founder and CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesHealthcare
Business model
B2B
Tags
pharmaceuticalscell-therapyamyotrophic-lateral-sclerosis-als
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neurogenesis-cell.com/ |
|---|
Identifiers & details
| Founded | 2005 |
|---|---|
| Employees (exact) | 5 |
| Offices | Rochester |
Radar intelligence
Patents
| EPO | 4 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | neurogenesis-cell.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515903466 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-09-16 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | תובל 11 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |